The commonly used costimulatory domains are CD28 and/or 4-1BB (CD137), and the second generation CARs targeting CD19 showed remarkable and durable efficacy in patients with lymphoma and leukemia of B cell origin [7, 8]. This evidence concerns the gene CD19 and lymphoma.